Liberate Bio Secures $31M Seed Funding

Liberate Bio has raised $31,000,000 from investors to advance its pioneering work in genetic medicine delivery.

The company is addressing a critical challenge in the field: the current limitation that confines most genetic medicines, such as mRNA, CRISPR, and gene therapies, primarily to the liver.

This funding round signifies a substantial commitment to overcoming this bottleneck and enabling broader applications for these transformative therapies.

At the core of Liberate Bio's approach is its proprietary RAPTOR™ platform.

This AI-driven system is designed to make extrahepatic genetic medicine scalable, moving beyond the slow, trial-and-error processes that traditionally dominate biotechnology.

The platform directly tests hundreds of novel lipid nanoparticles (LNPs) in non-human primates (NHPs) at a significantly reduced costreportedly 100 times lowercompared to conventional methods.

This process generates real-world, human-relevant data, which is crucial for developing safe and effective delivery systems that can target tissues beyond the liver.

The $31,000,000 investment will be strategically utilized to accelerate the development and expansion of the RAPTOR™ platform.

This capital infusion is expected to enable Liberate Bio to intensify its research and development efforts, refine its technology, and potentially broaden the scope of its LNP library.

By enhancing its capabilities, the company aims to expedite the discovery and optimization of delivery vehicles capable of targeting a wider range of organs and cell types.

This funding round underscores investor confidence in Liberate Bio's innovative solution to a fundamental problem in genetic medicine.

By providing a scalable and efficient means to deliver advanced therapies beyond the liver, the company is poised to unlock new therapeutic possibilities for a multitude of diseases.

Liberate Bio plans to leverage this capital to drive its growth initiatives and accelerate its mission to enable a new generation of genetic medicines, ultimately broadening the reach and impact of these life-changing treatments.